DEA and HHS Issue Final Telemdicine Rule for Buprenorphine Access

The Drug Enforcement Administration (DEA), together with the Department of Health and Human Services (HHS), finalized telemedicine flexibility regulations for the prescribing of medications for opioid use disorder, including buprenorphine.

This final rule makes permanent the buprenorphine-related telemedicine flexibilities that DEA and HHS had extended through the end of 2025.